Related Experiment Video

Updated: Jun 19, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Combination PPARgamma and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2

Joshua P Klopper1, Vibha Sharma, Reid Bissonnette

  • 1Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA.

PPAR Research
|October 28, 2009
PubMed

Insights

Nuclear hormone receptors like RXR and PPARgamma are key targets in melanoma. S100A2 expression influences response to rexinoid and thiazolidinedione treatments, impacting melanoma cell proliferation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Nuclear hormone receptors, specifically Retinoid X Receptor (RXR) and Peroxisome Proliferator-Activated Receptor gamma (PPARγ), are emerging therapeutic targets for melanoma.
  • Previous studies demonstrated that the A375(DRO) amelanotic melanoma subline exhibits sensitivity to rexinoid and thiazolidinedione (TZD) treatments both in vitro and in vivo.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying the response of A375(DRO) melanoma cells to rexinoid and TZD treatments.
  • To identify downstream mediators of RXR and PPARγ signaling in response to these therapeutic agents.

Main Methods:

  • Microarray analysis was performed on A375(DRO) cells following treatment with TZD and combination rexinoid/TZD therapies.
  • Functional studies involving overexpression and inhibition of S100A2 expression were conducted to assess its role in mediating treatment effects.

Main Results:

  • Microarray analysis revealed increased expression of the calcium-binding protein S100A2 upon rexinoid or TZD treatment, with a synergistic increase upon combination therapy.
  • Enhanced S100A2 expression potentiated the anti-proliferative effects of rexinoid and TZD, while its inhibition attenuated the response, indicating S100A2 is necessary for optimal treatment efficacy.
  • Increased S100A2 expression was dependent on an intact PPARγ receptor but was not sufficient on its own to mediate the antiproliferative effects.

Conclusions:

  • S100A2 is identified as a crucial mediator for optimal response to RXR and PPARγ activation by their respective ligands in a poorly differentiated melanoma model.
  • Alterations in S100A2 expression significantly impact RXR and PPARγ signaling pathways in A375(DRO) cells.
  • These findings provide valuable insights into the mechanisms of tumor response and potential resistance to novel therapies targeting nuclear hormone receptors in melanoma.

More Related Videos

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Experimental Metastasis Assay08:28

Experimental Metastasis Assay

Published on: August 24, 2010

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...